Quest Diagnostics
624 hedge funds and large institutions have $9.91B invested in Quest Diagnostics in 2018 Q4 according to their latest regulatory filings, with 70 funds opening new positions, 225 increasing their positions, 217 reducing their positions, and 110 closing their positions.
2.31% more ownership
Funds ownership: 86.36% → 88.67% (+2.3%)
4% more repeat investments, than reductions
Existing positions increased: 225 | Existing positions reduced: 217
7% less funds holding
Funds holding: 673 → 624 (-49)
22% less capital invested
Capital invested by funds: $12.7B → $9.91B (-$2.82B)
36% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 110
47% less call options, than puts
Call options by funds: $21.6M | Put options by funds: $41M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$135M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$106M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$93.8M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$79.1M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$70.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bessemer Group
Woodbridge,
New Jersey
|
-$121M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$97.7M |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$90.9M |
| 4 |
HM
HealthCor Management
New York
|
-$79.4M |
| 5 |
BlackRock
New York
|
-$72.1M |
DGX Hedge Fund Activity: Q4 2018 in Review
624 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q4 2018, worth a combined $9.91B — down 22% from $12.7B a quarter earlier.
Sellers outnumbered buyers: 110 funds closed out of DGX and 70 opened new positions — a net loss of 40 holders — while 217 trimmed existing stakes and 225 added.
The largest buyer was Levin Capital Strategies, opening a new position worth an estimated $135M. The largest seller was Bessemer Group, cutting an estimated $121M.
- 624 institutional investors held Quest Diagnostics (DGX) as of Q4 2018, down from 673 in Q3 2018.
- Funds reported $9.91B of Quest Diagnostics stock for Q4 2018, down 22% quarter-over-quarter.
- 70 funds opened new Quest Diagnostics positions in Q4 2018 and 110 closed out, a net change of -40 holders.
- The largest Quest Diagnostics buyer in Q4 2018 was Levin Capital Strategies, an estimated $135M added.
- The largest Quest Diagnostics seller in Q4 2018 was Bessemer Group, an estimated $121M sold.
Based on aggregated 13F filings for Q4 2018.